23andMe Holding Co. (ME)
NASDAQ (CM) NASDAQ (CM) Primary 
23andMe Stock Heads Toward Zero on Bankruptcy
23andMe Holding Co. (NASDAQ: ME) was a hot stock in late 2021, trading at $265.
23andMe Files for Bankruptcy
DNA-testing company 23andMe has filed for bankruptcy in the U.S. and announced the resignation of its chief executive.
23andMe special committee again rejects CEO Wojcicki's take-private offer
23andMe's special committee of independent directors on Monday rejected CEO Anne Wojcicki's proposal to take the distressed genetic testing company private. Wojcicki submitted a proposal to the committee on Sunday, offering to acquire all of the company's outstanding shares for 41 cents each.
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private. They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million.
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
23andMe Holding Co. (NASDAQ:ME ) Q2 2025 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Katie Watson - Vice President, Communications Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Chief Financial Officer & Chief Accounting Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the 23andMe Fiscal Year 2025 Second Quarter Earnings Call.
23andMe cuts 40% of staff in restructuring
23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials; it expects these changes to save $35 million annually.
23andMe reports sales decline day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The embattled genetic testing company said Monday that it's cutting about 200 jobs, or about 40% of its workforce, and discontinuing its therapeutics programs.
23andMe's stock turns lower after company posts its latest quarterly loss
Stock had gained late Monday on news it would cut 40% of its workforce as part of a restructuring.
23andMe to cut 40% of its workforce as it looks to stablise the business
Genetic testing firm 23andMe announced plans to cut 40% of its workforce, or around 200 jobs, as part of a cost-saving effort aimed at stabilising the company. It will also halt work on its therapy development projects, exploring options to license or sell them.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
